Published in Nat Med on August 01, 2001
Drug development from marine natural products. Nat Rev Drug Discov (2008) 4.08
Small-molecule-induced DNA damage identifies alternative DNA structures in human genes. Nat Chem Biol (2012) 2.41
Shining a light on xeroderma pigmentosum. J Invest Dermatol (2012) 2.33
Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov (2011) 1.80
Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res (2013) 1.80
Cockayne syndrome group B protein (CSB) plays a general role in chromatin maintenance and remodeling. Proc Natl Acad Sci U S A (2006) 1.64
Liposarcoma: molecular genetics and therapeutics. Sarcoma (2010) 1.55
SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. Clin Cancer Res (2015) 1.52
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A (2007) 1.43
BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder. Cell Cycle (2015) 1.41
Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia (2011) 1.37
Nucleotide excision repair and cancer. J Mol Histol (2006) 1.27
Meta-omic characterization of the marine invertebrate microbial consortium that produces the chemotherapeutic natural product ET-743. ACS Chem Biol (2011) 1.26
Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex. Mol Biol Cell (2008) 1.14
Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res (2008) 1.12
Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer (2014) 1.11
Cancer wars: natural products strike back. Front Chem (2014) 1.11
Identification of GAPDH as a protein target of the saframycin antiproliferative agents. Proc Natl Acad Sci U S A (2004) 1.07
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer (2007) 1.05
PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol (2010) 1.03
A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer (2006) 1.00
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol (2008) 0.97
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol (2008) 0.96
Genome maintenance and transcription integrity in aging and disease. Front Genet (2013) 0.95
Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer (2013) 0.93
Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin. Clin Cancer Res (2008) 0.91
Adding pharmacogenomics to the development of new marine-derived anticancer agents. J Transl Med (2006) 0.90
Histone methyltransferase DOT1L drives recovery of gene expression after a genotoxic attack. PLoS Genet (2013) 0.88
DNA and the chromosome - varied targets for chemotherapy. Cell Chromosome (2004) 0.88
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs (2010) 0.88
A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors. Pediatr Blood Cancer (2012) 0.86
Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma (2006) 0.86
Role of trabectedin in the treatment of soft tissue sarcoma. Onco Targets Ther (2009) 0.86
Trabectedin and its potential in the treatment of soft tissue sarcoma. Ther Clin Risk Manag (2008) 0.84
Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells. Mol Cancer (2010) 0.83
Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives. J Gynecol Oncol (2016) 0.82
Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age. Int J Oncol (2013) 0.82
Microarray-based transcriptional profiling of renieramycin M and jorunnamycin C, isolated from Thai marine organisms. Mar Drugs (2009) 0.82
Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer. Chin J Cancer (2015) 0.81
New drugs and combinations for the treatment of soft-tissue sarcoma: a review. Cancer Manag Res (2012) 0.80
BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients. Br J Cancer (2015) 0.79
Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin. Sarcoma (2015) 0.79
In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects. Br J Cancer (2003) 0.79
Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice. Invest New Drugs (2009) 0.79
Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin. Mol Cancer Ther (2009) 0.79
Trypanocidal activity of marine natural products. Mar Drugs (2013) 0.78
Regioselectivity of Pictet-Spengler Cyclization Reactions to Construct the Pentacyclic Frameworks of the Ecteinascidin-Saframycin Class of Tetrahydroisoquinoline Antitumor Antibiotics. Tetrahedron Lett (2007) 0.78
Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines. J Breast Cancer (2015) 0.78
Protein Recognition in Drug-Induced DNA Alkylation: When the Moonlight Protein GAPDH Meets S23906-1/DNA Minor Groove Adducts. Int J Mol Sci (2015) 0.77
Npl3, a new link between RNA-binding proteins and the maintenance of genome integrity. Cell Cycle (2014) 0.77
Expression of XPG protein in human normal and tumor tissues. Int J Clin Exp Pathol (2013) 0.77
Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin. Br J Cancer (2015) 0.77
Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Invest New Drugs (2011) 0.77
Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair. Oncotarget (2016) 0.76
Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis. BMC Cancer (2014) 0.76
Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary. PLoS One (2016) 0.75
Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics. Nat Prod Rep (2015) 0.75
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol (2015) 0.75
UV-induced proteolysis of RNA polymerase II is mediated by VCP/p97 segregase and timely orchestration by Cockayne syndrome B protein. Oncotarget (2016) 0.75
Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models. Neoplasia (2017) 0.75
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas. J Hematol Oncol (2017) 0.75
Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence. Onco Targets Ther (2014) 0.75
Molecular basis of differentiation therapy for soft tissue sarcomas. Trends Cancer Res (2016) 0.75
New developments in treatment of ovarian carcinoma: focus on trabectedin. Cancer Manag Res (2010) 0.75
Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line. Oncotarget (2016) 0.75
The G-quadruplex DNA stabilizing drug pyridostatin promotes DNA damage and downregulates transcription of Brca1 in neurons. Aging (Albany NY) (2017) 0.75
Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12. DNA Res (2001) 15.22
A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31
High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med (2001) 12.49
Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev (2001) 11.25
Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell (1996) 8.77
Cell-free translation reconstituted with purified components. Nat Biotechnol (2001) 6.55
Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol (1987) 5.88
Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science (1995) 5.65
Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J (2000) 5.61
Xeroderma pigmentosum. An inherited diseases with sun sensitivity, multiple cutaneous neoplasms, and abnormal DNA repair. Ann Intern Med (1974) 5.16
Phosphatidylinositol 4-phosphate 5-kinase alpha is a downstream effector of the small G protein ARF6 in membrane ruffle formation. Cell (1999) 4.98
Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev (2000) 4.38
Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem (2000) 4.36
Adenosine 3':5'-monophosphate-regulated phosphoprotein system of neuronal membranes. I. Solubilization, purification, and some properties of an endogenous phosphoprotein. J Biol Chem (1977) 4.33
Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes. Science (1989) 4.08
DNA polymerase eta is an A-T mutator in somatic hypermutation of immunoglobulin variable genes. Nat Immunol (2001) 4.00
Binocular rivalry and visual awareness in human extrastriate cortex. Neuron (1998) 3.59
The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol (2001) 3.58
Attentional requirements in a 'preattentive' feature search task. Nature (1997) 3.54
Priming of pop-out: I. Role of features. Mem Cognit (1994) 3.53
Arg-X-Lys/Arg-Arg motif as a signal for precursor cleavage catalyzed by furin within the constitutive secretory pathway. J Biol Chem (1991) 3.50
The human XPG gene: gene architecture, alternative splicing and single nucleotide polymorphisms. Nucleic Acids Res (2001) 3.45
An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J (1999) 3.42
cDNA cloning of bovine substance-K receptor through oocyte expression system. Nature (1987) 3.31
Escherichia coli RecQ protein is a DNA helicase. Proc Natl Acad Sci U S A (1990) 3.27
Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J (1999) 3.13
Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet (2000) 3.06
Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. Cancer Res (1999) 3.06
Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology (1995) 2.99
The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene (2001) 2.97
Restoration of T cell development in RAG-2-deficient mice by functional TCR transgenes. Science (1993) 2.93
Isolation and genetic characterization of a thymineless death-resistant mutant of Escherichia coli K12: identification of a new mutation (recQ1) that blocks the RecF recombination pathway. Mol Gen Genet (1984) 2.92
Molecular cloning and characterization of a novel type of regulatory protein (GDI) for the rho proteins, ras p21-like small GTP-binding proteins. Oncogene (1990) 2.89
Essential role for ZAP-70 in both positive and negative selection of thymocytes. Nature (1995) 2.88
Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta (1998) 2.83
Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene (1990) 2.80
Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. Science (1993) 2.68
Targeted disruption of Bcl-2 alpha beta in mice: occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proc Natl Acad Sci U S A (1994) 2.66
Regulation of endogenous phosphorylation of specific proteins in synaptic membrane fractions from rat brain by adenosine 3':5'-monophosphate. J Biol Chem (1973) 2.66
Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res (1998) 2.59
Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology (1991) 2.54
Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med (1985) 2.54
Serial and parallel processing of visual feature conjunctions. Nature (1986) 2.51
NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. Mol Cell Biol (1996) 2.51
Photoproduct frequency is not the major determinant of UV base substitution hot spots or cold spots in human cells. Proc Natl Acad Sci U S A (1987) 2.50
A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature (2001) 2.48
Occurrence of N-nonsubstituted glucosamine residues in peptidoglycan of lysozyme-resistant cell walls from Bacillus cereus. J Biol Chem (1972) 2.45
NAK is an IkappaB kinase-activating kinase. Nature (2000) 2.44
Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff. Mol Cell Biol (2000) 2.41
Subcellular distribution in cerebral cortex of two proteins phosphorylated by a cAMP-dependent protein kinase. J Cell Biol (1979) 2.40
Genetic analyses of proteolysis, hemoglobin binding, and hemagglutination of Porphyromonas gingivalis. Construction of mutants with a combination of rgpA, rgpB, kgp, and hagA. J Biol Chem (1999) 2.39
ACE inhibitors and pneumonia. Lancet (1998) 2.38
DNA repair protects against cutaneous and internal neoplasia: evidence from xeroderma pigmentosum. Carcinogenesis (1984) 2.35
Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res (1994) 2.34
Genetic heterogeneity in xeroderma pigmentosum: complementation groups and their relationship to DNA repair rates. Proc Natl Acad Sci U S A (1975) 2.29
A cytotoxic ribonuclease targeting specific transfer RNA anticodons. Science (1999) 2.29
Involvement of the IRF-1 transcription factor in antiviral responses to interferons. Science (1994) 2.28
Cockayne syndrome and xeroderma pigmentosum. Neurology (2000) 2.24
Degradation of p27(Kip1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem (2001) 2.23
Motion perception in schizophrenia. Arch Gen Psychiatry (1999) 2.20
Role of the extra G-C pair at the end of the acceptor stem of tRNA(His) in aminoacylation. Nucleic Acids Res (1989) 2.18
The recQ gene of Escherichia coli K12: molecular cloning and isolation of insertion mutants. Mol Gen Genet (1985) 2.16
Topoisomerase I-mediated DNA damage. Adv Cancer Res (2001) 2.16
New graft-implanting method for thoracic aortic aneurysm or dissection with a stented graft. Circulation (1996) 2.14
A new cdc gene required for S phase entry of Schizosaccharomyces pombe encodes a protein similar to the cdc 10+ and SWI4 gene products. EMBO J (1992) 2.14
Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J Med Chem (1999) 2.10
Derivation of human tumor cells in vitro without widespread genomic instability. Cancer Res (2001) 2.07
Mouse Ror2 receptor tyrosine kinase is required for the heart development and limb formation. Genes Cells (2000) 2.05
Ubiquitin-dependent degradation of IkappaBalpha is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. Proc Natl Acad Sci U S A (1999) 2.04
Differential expression of bcl-2 in intestinal epithelia. Correlation with attenuation of apoptosis in colonic crypts and the incidence of colonic neoplasia. J Cell Sci (1995) 2.01
Glue embolization for gastroduodenal ulcer bleeding: contribution to hemodynamics and healing process. Acta Radiol (2013) 1.98
Widespread distribution of protein I in the central and peripheral nervous systems. Proc Natl Acad Sci U S A (1979) 1.98
Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin. Mol Cell Biol (1999) 1.97
Immunocytochemical localization, in synapses, of protein I, an endogenous substrate for protein kinases in mammalian brain. Proc Natl Acad Sci U S A (1979) 1.96
Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors. Oncogene (2007) 1.95
Non-universal decoding of the leucine codon CUG in several Candida species. Nucleic Acids Res (1993) 1.94
Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res (1989) 1.94
Identification and subcellular localization of a novel mammalian dynamin-related protein homologous to yeast Vps1p and Dnm1p. J Biochem (1997) 1.94
Proprotein-processing endoproteases PC6 and furin both activate hemagglutinin of virulent avian influenza viruses. J Virol (1994) 1.93
Restricted ultraviolet mutational spectrum in a shuttle vector propagated in xeroderma pigmentosum cells. Proc Natl Acad Sci U S A (1986) 1.92
Mammalian subtilisin-related proteinases in cleavage activation of the paramyxovirus fusion glycoprotein: superiority of furin/PACE to PC2 or PC1/PC3. J Virol (1992) 1.91
High sensitivity C-reactive protein in asthma. Eur Respir J (2006) 1.91
Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci U S A (1993) 1.91
Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine. J Biol Chem (1999) 1.91
Five complementation groups in xeroderma pigmentosum. Mutat Res (1975) 1.91
Molecular genetics and nomenclature of proteases of Porphyromonas gingivalis. J Periodontal Res (1999) 1.90
Priming of pop-out: II. The role of position. Percept Psychophys (1996) 1.85
Structure and expression of mouse furin, a yeast Kex2-related protease. Lack of processing of coexpressed prorenin in GH4C1 cells. J Biol Chem (1990) 1.85
Robust representations for faces: evidence from visual search. J Exp Psychol Hum Percept Perform (1999) 1.85
Trichothiodystrophy: a systematic review of 112 published cases characterises a wide spectrum of clinical manifestations. J Med Genet (2008) 1.85
A novel lysine-substituted nucleoside in the first position of the anticodon of minor isoleucine tRNA from Escherichia coli. J Biol Chem (1988) 1.85
A dominant negative mutant of sar1 GTPase inhibits protein transport from the endoplasmic reticulum to the Golgi apparatus in tobacco and Arabidopsis cultured cells. Plant J (2000) 1.84